Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carliprazine
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carliprazine (KH110) is a novel small-molecule antipsychotic developed by Chengdu Kanghong Pharmaceutical Group for the treatment of schizophrenia. It acts as a partial agonist at the dopamine D3 and D2 receptors, with a notably high affinity for the D3 subtype, and also functions as a partial agonist at the serotonin 5-HT1A receptor. This pharmacological profile is intended to manage the positive, negative, and cognitive symptoms of schizophrenia while potentially minimizing side effects such as weight gain and extrapyramidal symptoms. The drug is currently in Phase 3 clinical development in China, where it is being evaluated in a non-inferiority study compared to aripiprazole in patients with acute schizophrenia.
- Other names
- Carliprazine hydrochlorideHydrochloride carliprazine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on Carliprazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carliprazine.